Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
299.31B
Market cap299.31B
Price-Earnings ratio
16.60
Price-Earnings ratio16.60
Dividend yield
2.75%
Dividend yield2.75%
Average volume
11.25M
Average volume11.25M
High today
$121.48
High today$121.48
Low today
$120.05
Low today$120.05
Open price
$120.41
Open price$120.41
Volume
600.06K
Volume600.06K
52 Week high
$125.14
52 Week high$125.14
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

As of today, Merck(MRK) shares are valued at $121.06. The company's market cap stands at 299.31B, with a P/E ratio of 16.60 and a dividend yield of 2.7%.

As of 2026-04-06, Merck(MRK) stock has fluctuated between $120.05 and $121.48. The current price stands at $121.06, placing the stock +0.8% above today's low and -0.3% off the high.

The Merck(MRK)'s current trading volume is 600.06K, compared to an average daily volume of 11.25M.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $125.14 at its peak.

During the past year, Merck(MRK) stock moved between $73.31 at its lowest and $125.14 at its peak.

MRK News

TipRanks 59m
Merck price target raised to $135 from $125 at JPMorgan

JPMorgan analyst Chris Schott raised the firm’s price target on Merck (MRK) to $135 from $125 and keeps an Overweight rating on the shares ahead of the earnings...

Simply Wall St 20h
Assessing Merck Valuation After Keytruda EU Approval And Strong Oral PCSK9 Phase 3 Results

Merck (MRK) is back in focus after two key milestones: strong Phase 3 data for its oral PCSK9 candidate enlicitide decanoate, and fresh EU approval expanding Ke...

Assessing Merck Valuation After Keytruda EU Approval And Strong Oral PCSK9 Phase 3 Results
TipRanks 4d
Merck’s Keytruda in combination approved in EU for ovarian carcinoma

Merck (MRK) announced that Keytruda – pembrolizumab -, in combination with paclitaxel, with or without bevacizumab, is approved in the European Union, or EU, fo...

Analyst ratings

67%

of 30 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

More MRK News

Simply Wall St 5d
Merck Taps Infinimmune AI Antibodies To Support Long Term Growth Narrative

Merck (NYSE:MRK) has entered into a collaboration with Infinimmune to use AI-driven antibody discovery and engineering technologies. The deal gives Merck exclu...

Merck Taps Infinimmune AI Antibodies To Support Long Term Growth Narrative
Benzinga 5d
Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs

The agreement enables Merck to leverage Infinimmune's proprietary technologies to identify therapies targeting multiple undisclosed programs. Merck Secures Exc...

Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs
Investor's Business Daily 6d
Dow Jones Drug Giant Merck, Costco Approach New Buy Points

Stocks Near A Buy Zone Dow Jones Drug Giant Merck, Costco Approach New Buy Points Licensing As the Dow Jones Industrial Average and other stock indexes traded h...

Dow Jones Drug Giant Merck, Costco Approach New Buy Points
Nasdaq 6d
Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Merck & Co Inc (Symbol: MRK) is the #8 broker pick, on average, out of the 30 stocks makin...

Broker Darlings of the Dow: Merck Ranks As a Top 15 Analyst Pick
Nasdaq 6d
Merck Just Made a Big Bet on a New Cancer Growth Engine

While the health care sector has struggled this year, that hasn’t been the case for all of Big Pharma. Shares of New Jersey-based Merck & Co. (NYSE: MRK) have...

Merck Just Made a Big Bet on a New Cancer Growth Engine
Simply Wall St 6d
Merck Cardiovascular Readouts Point To New Growth Drivers Beyond Oncology

Merck (NYSE:MRK) reported positive Phase 3 results for its oral PCSK9 inhibitor, enlicitide decanoate, showing marked LDL C reduction and a favorable safety pro...

Merck Cardiovascular Readouts Point To New Growth Drivers Beyond Oncology
TipRanks 7d
Merck announces results from CORALreef AddOn study of enlicitide decanoate

Merck (MRK) announced detailed results from CORALreef AddOn, an active comparator study designed to evaluate the efficacy and safety of enlicitide decanoate com...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.